Strong First-Week U.S. Prescriptions Propel Novo Nordisk Shares 9.1% After Oral Wegovy Launch
Novo Nordisk’s shares surged 9.1% on indications that oral Wegovy secured robust first-week U.S. prescriptions following its early January launch. The strong uptake signals significant demand for the company’s first oral GLP-1 weight-loss therapy.
1. Ozempic Drives Record Revenue Growth
Novo Nordisk reported Ozempic sales of $17 billion in 2024 and projects up to $25 billion for 2025, cementing the GLP-1 therapy’s status as a cornerstone of the company’s growth. The weight-loss indication, an unintended offshoot of its original diabetes treatment, has propelled Novo Nordisk’s market value above $500 billion—surpassing Denmark’s entire GDP—and positioned the company as one of Europe’s most valuable stocks.
2. Robust Obesity Pipeline Under Development
Building on the success of Ozempic and Wegovy, Novo Nordisk is advancing next-generation obesity candidates. Amycretin entered FDA Phase 1 trials after demonstrating a 13.1% average weight loss at 12 weeks in early studies, more than doubling current efficacy benchmarks. CagriSema, a combination of semaglutide with amylin and calcitonin receptor agonists, has moved into Phase 2 studies with expectations for late-stage data by year-end. Management plans to initiate Phase III trials for amycretin in Q1 2026 and anticipates oral weight-loss drugs to capture over one-third of the GLP-1 market by 2030.
3. Legal and Regulatory Headwinds
Novo Nordisk faces 235 active product liability lawsuits related to Ozempic as of August 2024, while a U.S. Senate investigation confirmed pricing increases of 1 500% versus European markets. Regulatory fines have included a $59 million DOJ penalty in 2017 for nondisclosure of cancer risks with Victoza, and suspension from the UK Pharmacy Industry association over ethics concerns. In November 2025, the company agreed to lower GLP-1 drug prices under a U.S. administration deal, and maintains that outstanding lawsuits will be dismissed or settled without derailing growth.
4. Strategic Acquisitions and Global Expansion
Novo Nordisk has invested over $10 billion in acquisitions since 2020 to diversify its portfolio and scale production. Key deals include the $3.3 billion purchase of Dicerna Pharmaceuticals in 2021 for RNAi therapeutics, the $1 billion acquisition of Inversago Pharma in 2023, and the up-to-$5.2 billion closing of Akero Therapeutics in 2025. Market expansion highlights include Wegovy’s approval for China in mid-2024 and Health Canada’s Rybelsus indication for cardiovascular risk reduction. These moves, combined with new manufacturing facilities and the parent Novo Holdings’ 2024 acquisition of Catalent, aim to mitigate geopolitical risks and capture emerging markets through 2030.